911295-24-4
中文名稱
MPP 二鹽酸鹽
英文名稱
Methyl-piperidino-pyrazole hydrate
CAS
911295-24-4
分子式
C29H32ClN3O3
分子量
506.04
MOL 文件
911295-24-4.mol
更新日期
2024/12/16 15:20:13
911295-24-4 結(jié)構(gòu)式
基本信息
中文別名
MPP 二鹽酸鹽化合物 T12101
化合物MPP DIHYDROCHLORIDE (289726-02-9 FREE BASE)
英文別名
MPP dihydrochloride hydrateMethyl-piperidino-pyrazole hydrate
MPP dihydrochloride (289726-02-9 Free base)
Methyl-piperidino-pyrazole dihydrochloride hydrate
MPP dihydrochloride (289726029 Free base),MPP dihydrochloride (289726 02 9 Free base)
1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride hydrate
安全數(shù)據(jù)
常見問題列表
生物活性
MPP dihydrochloride 是一種高度選擇性的雌激素受體 α (ERα) 拮抗劑。MPP dihydrochloride 降低了 p-ERα/ERα 的比率。體外研究
MPP (1, 5, 10, 25, 50 and 100 μM; 24 h) decreases cell viability with an IC
50
value of 20.01 μM in RL95-2 cells.
MPP dihydrochloride shows antiproliferative activity at a concentration of 10 μM in RL95-2 cells.
MPP dihydrochloride (20 μM; 24 h) reduces the phosphorylation of ERα, while it does not alter the phosphorylation of Akt. MPP dihydrochloride reduces the ratio of p-ERα/ERα.
Cell Viability Assay
| Cell Line: | RL95-2 endometrium cancer cells |
| Concentration: | 1, 5, 10, 25, 50 and 100 μM |
| Incubation Time: | 24 hours |
| Result: | The treatment with 25 μM, 50 μM and 100 μM for 24 h decreased cell viability significantly. However, cell viability was not significantly changed by MPP dihydrochloride at concentration below 25 μM. |
Cell Proliferation Assay
| Cell Line: | RL95-2 cell |
| Concentration: | 10, 15, 20 and 25 μM |
| Incubation Time: | 72 hours |
| Result: | Showed antiproliferative activity at a concentration of 10 μM. |
Western Blot Analysis
| Cell Line: | RL95-2 cell line |
| Concentration: | 20 μM |
| Incubation Time: | 24 hours |
| Result: | Reduced the phosphorylation of ERα, while it did not alter the phosphorylation of Akt. Reduced the ratio of p-ERα/ERα compared to the control group. |
體內(nèi)研究
MPP (Low dose 20 μg/kg body weight or high dose 200 μg/kg body weight) leads to a dose-dependent attenuation of percent prepulse inhibition (PPI).
| Animal Model: | Male C57BL/6N mice at the age of 9-10 weeks |
| Dosage: | Low dose (20 μg/kg body weight) or high dose (200 μg/kg body weight) |
| Administration: | Administered subcutaneously (s.c.) injected; injection volume of 5 mL/kg; 60 min before PPI testing |
| Result: | Led to a dose-dependent attenuation of percent PPI. Pretreatment with 200 μg/kg reduced the mean percent PPI scores by ~30%. |